Dramatic resolution of choroidal neovascular abnormalities after single aflibercept injection following years of ranibizumab use

JAMA Ophthalmol. 2013 Feb;131(2):260-2. doi: 10.1001/jamaophthalmol.2013.1733.

Authors

Voraporn Chaikitmongkol¹, Neil M Bressler

Affiliation

¹ Retina Division, Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

PMID: 23411901
DOI: 10.1001/jamaophthalmol.2013.1733

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Capillary Permeability
Choroidal Neovascularization / drug therapy*
Choroidal Neovascularization / physiopathology
Fluorescein Angiography
Humans
Intravitreal Injections
Macular Edema / drug therapy
Macular Edema / physiopathology
Male
Photochemotherapy
Ranibizumab
Receptors, Vascular Endothelial Growth Factor / administration & dosage*
Recombinant Fusion Proteins / administration & dosage*
Remission Induction
Tomography, Optical Coherence
Visual Acuity / physiology

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Recombinant Fusion Proteins
aflibercept
Receptors, Vascular Endothelial Growth Factor
Ranibizumab